Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M最新文献_第5页

The EAMG position on the regulation of existing products for treatment with special reference to named patient products (NPPs). EAMG对现有治疗产品的监管立场，特别提及命名患者产品(NPPs)。

Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M Pub Date : 2003-01-01

Albert M Kroon

{"title":"The EAMG position on the regulation of existing products for treatment with special reference to named patient products (NPPs).","authors":"Albert M Kroon","doi":"","DOIUrl":"","url":null,"abstract":"Allergen products have a long history in both diagnosis and management of allergic disease. It is emphasized that the availability of named patient products presents a valuable and indispensable option for the effective and safe treatment of patients suffering from IgE-mediated allergic diseases. A regulatory climate should be achieved in which these products can survive until a safe and effective alternative is borne out. Within the context of the paper the following definition is used: A named patient product or NPP is an allergen product, prepared with a specific reference number in accordance with a prescription for an individual patient, identified by the name of this patient and the reference number, and delivered after control of consistency with previous treatments. It is stressed that the standards of quality that hold for registered products are also applicable for named patient preparations which, for various reasons, can not be filed for registration. The paper frequently refers to a Position Paper that has recently been adopted by the European Allergen Manufacturers Group, the EAMG. The presentation breaks a lance for a concerted approach of the NPP-concept by striving at harmonization of legal, regulatory, manufacturing, and distribution conditions.","PeriodicalId":77490,"journal":{"name":"Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M","volume":" 94","pages":"7-14; discussion 14-6"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24497605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peptide-based immunotherapy: new developments. 基于肽的免疫治疗:新进展。

Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M Pub Date : 2003-01-01

Mark Larché

引用次数: 0

Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: in vitro and in vivo evaluation. 犹太顶棚主要过敏原的低过敏性变异:体外和体内评估。

Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M Pub Date : 2003-01-01

Paolo Colombo

引用次数: 0

Engineering and validation of recombinant proteins for allergen vaccines. 过敏原疫苗重组蛋白的工程和验证。

Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M Pub Date : 2003-01-01

Michael D Spangfort

引用次数: 0

Recombinant food allergens in the diagnosis of pollen-related food allergy. 重组食物过敏原在花粉相关食物过敏诊断中的应用。

Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M Pub Date : 2003-01-01

Barbara K Ballmer-Weber, Andrea Wangorsch, Stephan Scheurer

引用次数: 0

Alternative approaches to immunotherapy of allergy. 过敏免疫治疗的替代方法。

Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M Pub Date : 2003-01-01

Irwin Ziment

{"title":"Alternative approaches to immunotherapy of allergy.","authors":"Irwin Ziment","doi":"","DOIUrl":"","url":null,"abstract":"Alternative therapies for allergic diseases may be prescribed by physicians or provided by other practitioners or selected by patients without resorting to consultation with a health advisor. The most popular alternative therapies include dietary manipulation and exaggerated avoidance of allergens. Established medical therapies include herbs (Western and Asian), homeopathy and acupuncture; many publications suggest they are of value in allergic disease management. However, most studies lack sufficient power, do not have adequate controls, fail to duplicate standard clinical practices, or utilize a heterogeneous group of subjects. Careful analysis suggest that popular alternative therapies might offer a minimal benefit over placebos, but further studies are required for more rigorous evaluation of outcomes. Numerous esoteric or non-specific methods of treating allergic diseases are also available which may be promoted by enthusiastic practitioners or supported by satisfied patients. The majority of such therapies will never be scientifically evaluated, and the results of such modalities will be difficult to separate out from those of true placebo treatments. It is evident that while the \"prose\" of scientifically established therapies is appealing to a declining number of patients, the \"poetry\" of complementary therapies resonates with an increasing majority of the public who believe in the magic of alternative medicine.","PeriodicalId":77490,"journal":{"name":"Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M","volume":" 94","pages":"247-57; discussion 257-9"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24496892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Parallels between parasite infections and specific immunotherapy. 寄生虫感染与特异性免疫治疗的相似之处。

Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M Pub Date : 2003-01-01

Ronald van Ree, Maria Yazdanbakhsh

引用次数: 0

Mechanisms of immunotherapy with allergoids: lessons for the development of recombinant allergens with reduced IgE-binding activity. 类过敏原免疫治疗的机制:开发具有降低ige结合活性的重组过敏原的经验教训。

Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M Pub Date : 2003-01-01

Oliver Cromwell, Helga Kahlert, Gabriele Schramm, Roland Suck, Andreas Nandy, Bernhard Weber, Helmut Fiebig

引用次数: 0

Criteria for clinical efficacy--readout and monitoring of clinical studies. 临床疗效标准——临床研究的读数和监测。

Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M Pub Date : 2003-01-01

Hans-Jørgen Malling

引用次数: 0

Expression of allergens in E. coli and plants--benefits and drawbacks. 大肠杆菌和植物中过敏原的表达——利弊。

Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M Pub Date : 2003-01-01

Heimo Breiteneder, Birgit Wagner

引用次数: 0